Q-omics provides the consensus-scored FBXO30-DT profile across patient tissues and cancer cell-line models. FBXO30-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FBXO30-DT is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, FBXO30-DT RNA expression shows 20,696 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where FBXO30-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO30-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO30-DT survival associations across molecular data types. FBXO30-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO30-DT RNA expression–survival associations across cancer types. High FBXO30-DT expression shows unfavorable associations in BLCA, but favorable associations in ACC, SKCM, HNSC, KIRP and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FBXO30-DT RNA expression.
This table summarizes FBXO30-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO30-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO30-DT shows lower tumor expression in THCA, KICH, KIRC, COAD, UCEC and BLCA. The THCA box plot shows higher FBXO30-DT RNA expression in normal versus tumor tissue (log2 FC = −1.045, t-test p < 0.001).
This table shows molecular features associated with FBXO30-DT in patient tissues and cancer cell lines. In patient samples, FBXO30-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
